References
- Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med. 2006;355(23):2452–66.
- Briere JB. Essential thrombocythemia. Orphanet J Rare Dis. 2007;2:3.
- Johansson P. Epidemiology of the myeloproliferative disorders polycythemia vera and essential thrombocythemia. Semin Thromb Hemost. 2006;32(3):171–3.
- Barbui T, Finazzi G, Dupuy E, Kiladjian JJ, Briere J. Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centers. Leuk Lymphoma. 1996;22 (Suppl 1):149–60.
- Hoffman R. Quality of life issues in patients with essential thrombocythemia and polycythemia vera. Semin Oncol. 2002;29 (3 Suppl 10):3–9.
- Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2008;22(1):14–22.
- Girodon F, Bonicelli G, Schaeffer C, Mounier M, Carillo S, Lafon I, et al. Significant increase in the apparent incidence of essential thrombocythemia related to new WHO diagnostic criteria: a population-based study. Hematologica. 2009;94(6):865–9.
- Reilly JT. Anagrelide for the treatment of essential thrombocythemia: a survey among European hematologists/oncologists. Hematology. 2009;14(1):1–10.
- Harrison C. Rethinking disease definitions and therapeutic strategies in essential thrombocythemia and polycythemia vera. Hematology Am Soc Hematol Educ Program. 2010;2010:129–34.
- Harrison CN, Bareford D, Butt N, Campbell P, Conneally E, Drummond M, et al. Guideline for investigation and management of adults and children presenting with a thrombocytosis. Br J Hematol. 2010;149(3):352–75.
- Beer PA, Green AR. Pathogenesis and management of essential thrombocythemia. Hematology Am Soc Hematol Educ Program. 2009;2009:621–8.
- Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011;29(6):761–70.
- Barbui T, Barosi G, Grossi A, Gugliotta L, Liberato LN, Marchetti M, et al. Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Hematologica. 2004;89(2):215–32.
- Mazzucconi MG, De Sanctis V, Chistolini A, Dragoni F, Mandelli F. Therapy with Anagrelide in patients affected by essential thrombocythemia: preliminary results. Hematologica. 1992;77(4):315–7.
- EMEA. (European Medicines Agency). Xagrid. Summary of Product Characteristics. 2009. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000480/WC500056557.pdf (last accessed April 2011).
- Petrides PE, Beykirch MK, Trapp OM. Anagrelide, a novel platelet lowering option in essential thrombocythemia: treatment experience in 48 patients in Germany. Eur J Hematol. 1998;61(2):71–6.
- Mills AK, Taylor KM, Wright SJ, Bunce I, Eliadis P, Brigden MC, et al. Efficacy, safety and tolerability of anagrelide in the treatment of essential thrombocythemia. Aust N Z J Med. 1999;29(1):29–35.
- Kornblihtt LI, Vassallu PS, Heller P, Molinas FC. [Treatment of essential thrombocythemia with anagrelide: a ten-year experience]. Medicina (B Aires). 2002;62(3):231–6.
- Mazur G, Wróbel T, Podolak-Dawidziak M, Kuliszkiewicz-Janus M, Potoczek S, Nosol J, et al. [Anagrelide in the treatment of thrombocythemia essential (ET)]. Pol Arch Med Wewn. 2004;112(6):1445–50.
- Griesshammer M, Bangerter M, Grunewald M. Current treatment practice for essential thrombocythemia in adults. Expert Opin Pharmacother. 2001;2(3):385–93.
- Barosi G, Birgegard G, Finazzi G, Griesshammer M, Harrison C, Hasselbalch HC, et al. Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood. 2009;113(20):4829–33.
- Barosi G, Besses C, Birgegard G, Briere J, Cervantes F, Finazzi G, et al. A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group. Leukemia. 2007;21(2):277–80.
- Reilly JT. Implications of the consensus definition of clinical resistance and intolerance to hydroxyurea for clinical practice. Eur J Hematol Suppl. 2007;79(68):32–4.